552 related articles for article (PubMed ID: 14631615)
41. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
42. Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease.
Tripatara A; Jetsrisuparb A; Teeratakulpisarn J; Kuaha K
Thromb Res; 2007; 120(6):805-10. PubMed ID: 17382994
[TBL] [Abstract][Full Text] [Related]
43. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
[TBL] [Abstract][Full Text] [Related]
44. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
45. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.
Ataga KI; Cappellini MD; Rachmilewitz EA
Br J Haematol; 2007 Oct; 139(1):3-13. PubMed ID: 17854302
[TBL] [Abstract][Full Text] [Related]
46. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
47. Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report.
Ahmed S; Siddiqui AK; Iqbal U; Sison CP; Shahid RK; Sheth M; Patel DV; Russo LA
Eur J Haematol; 2004 Mar; 72(3):213-6. PubMed ID: 14962240
[TBL] [Abstract][Full Text] [Related]
48. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
49. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
[TBL] [Abstract][Full Text] [Related]
50. Effect of hydroxyurea on immature reticulocyte fraction in sickle cell anemia.
Bagdasaryan R; Glasser L; Quillen K; Chaves F; Xu D
Lab Hematol; 2007; 13(3):93-7. PubMed ID: 17984040
[TBL] [Abstract][Full Text] [Related]
51. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
52. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
Ulug P; Vasavda N; Kumar R; Keir L; Awogbade M; Cunningham J; Rees DC; Menzel S; Thein SL
Am J Hematol; 2008 Sep; 83(9):714-6. PubMed ID: 18615556
[TBL] [Abstract][Full Text] [Related]
53. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
54. Protein C and S and inflammation in sickle cell disease.
Schnog JB; Mac Gillavry MR; van Zanten AP; Meijers JC; Rojer RA; Duits AJ; ten Cate H; Brandjes DP
Am J Hematol; 2004 May; 76(1):26-32. PubMed ID: 15114593
[TBL] [Abstract][Full Text] [Related]
55. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
56. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
57. Plasma protein Z and protein C inhibitors and their role in hypercoagulability of thalassemia.
Del Vecchio GC; Nigro A; Giordano P; Schettini F; Altomare M; Pietrapertosa A; De Mattia D
Acta Haematol; 2007; 118(3):136-40. PubMed ID: 17804900
[TBL] [Abstract][Full Text] [Related]
58. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.
Rigano P; Pecoraro A; Calzolari R; Troia A; Acuto S; Renda D; Pantalone GR; Maggio A; Di Marzo R
Br J Haematol; 2010 Dec; 151(5):509-15. PubMed ID: 20955403
[TBL] [Abstract][Full Text] [Related]
59. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
Cartron JP; Elion J
Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
[TBL] [Abstract][Full Text] [Related]
60. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia.
Helley D; Eldor A; Girot R; Ducrocq R; Guillin MC; Bezeaud A
Thromb Haemost; 1996 Sep; 76(3):322-7. PubMed ID: 8883264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
